Skip to content

Source filing unavailable

Q2 2014 · —
Revenue$21.00K−84.2% vs Q2 2013−87.7% vs Q1 2014
Net Income-$16.43Mno prior Q2 2013 on fileN/M vs Q1 2014
EPS Diluted-$0.55N/M vs Q2 2013N/M vs Q1 2014
Operating Income-$16,448,000N/M
Operating Cash Flowderived-$11,882,000N/M
Free Cash Flowderived-$12,206,000—
Margins · derived
Operating margin-78323.8%−73158.4 pt vs Q2 2013
Net margin-78242.9%

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ2 2014Q2 2013Q2 2012
Revenue$21.00K$133.00K$533.00K
Net Income-$16.43M——
EPS Diluted-$0.55-$2.86-$2.37

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Karyopharm Therapeutics Inc. · CIK 1503802 · Engraved from SEC EDGAR